Monitoring anticoagulated patients who suffer head injury
Prospective, multi-centre, pragmatic observational cohort study
Professor Suzanne Mason
Dr. Matt Reed
Mason S, Kuczawski M, Teare M, Stevenson M, Holmes M, Ramlakhan S, Goodacr S, Morris F, Harper R: THE AHEAD STUDY: MANAGING ANTICOAGULATED PATIENTS WHO SUFFER HEAD INJURY. Emergency Medicine Journal (2014);31:775
The study with PP100-01 in combination with NAC is designed to determine safety and tolerability of PP100-01 when co-administered with NAC as compared to the 12-hr NAC treatment regime for patients that come to the hospital after an overdose of paracetamol/acetaminophen.
A Randomised Open Label Exploratory, Safety and Tolerability Study with PP100-01 in Patients Treated with the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose
1. Ambulatory Device, Rocket Pleural vent insertion
2. Standard Treatment, Aspiration +/- chest drain
Primary Outcome Measures
To assess whether use of an ambulatory device (Rocket Pleural Vent) and treatment strategy reduces hospital stay. Total length of stay in hospital up to 30 days post randomisation. Up to 30 days post randomisation.
RAMPP trial - Randomised Controlled Trial: Pleural vent (rocket) V standard care in Primary Spontaneous Pnuemothorax